In a previous retrospective analysis, we demonstrated that quantifying Programmed Cell Death Ligand 1 (PD-L1) expression using a phosphor-integrated dot (PID) score effectively predicted the efficacy of immune checkpoint inhibitors (ICIs) across various cancers, including non-small cell lung cancer (NSCLC) (1). Here, CD274 is linked to non-small cell lung carcinoma.